Australia's Neuren Pharma jump on positive trial results to treat Pitt-Hopkins

Neuren Pharmaceuticals

27/05/2024 04:48

** Shares of Australia's Neuren Pharmaceuticals  NEU.AX 
rise as much as 11.8% to A$23.16, hitting their highest since
Feb. 15
    ** The drug-maker announces positive trial results for its
proposed treatment for Pitt-Hopkins syndrome
    ** Pitt-Hopkins is a very rare genetic disorder where
individuals develop distinctive facial features and is marked by
intellectual disabilities and problems with socailizing
    ** Shares on track for biggest intraday pct gain since Dec.
2023
    ** Stock has fallen 17.1% this year, as of last close

 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))